Status:

COMPLETED

Effect of Baclofen on Marijuana Withdrawal and Relapse

Lead Sponsor:

New York State Psychiatric Institute

Collaborating Sponsors:

National Institute on Drug Abuse (NIDA)

Conditions:

Marijuana Dependence

Eligibility:

All Genders

21-45 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to determine if baclofen dose-dependently decreases marijuana's direct effects and symptoms of marijuana withdrawal and thus decreases marijuana relapse.

Detailed Description

Only a small percentage of dependent-marijuana smokers who are seeking treatment for their marijuana use are able to achieve sustained abstinence. The objective of this study is to investigate the int...

Eligibility Criteria

Inclusion

  • Current marijuana use: average of 3 marijuana cigarettes at least 4 times per week for the past 4 weeks
  • Able to perform study procedures
  • 21-45 years of age
  • Women practicing an effective form of birth control (condoms, diaphragm, birth control pill, IUD)

Exclusion

  • Current, repeated illicit drug use (other than marijuana)
  • Presence of significant medical illness(e.g., diabetes, cardiovascular disease, hypertension, examination, laboratory clinically significant laboratory abnormalities)
  • History of heart disease
  • Request for drug treatment
  • Current parole or probation
  • Pregnancy or current lactation
  • Recent history of significant violent behavior
  • Major current Axis I psychopathology(e.g., major depressive disorder, bipolar disorder, suicide risk, schizophrenia)
  • Current use of any prescription or over-the-counter medication

Key Trial Info

Start Date :

May 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2010

Estimated Enrollment :

13 Patients enrolled

Trial Details

Trial ID

NCT00373295

Start Date

May 1 2006

End Date

January 1 2010

Last Update

May 10 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

New York State Psychiatric Institute

New York, New York, United States, 10032